Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Vuk Zdinjak

Cannabis Users Can Track Their Consumption With New Journal App From Juva Life

Juva Life Inc. (CSE:JUVA) (OTCQB:JUVAF) (FRANKFURT:4VV) launched the Journal App, designed to help cannabis users and patients track their consumption, and gain insight into how cannabis products affect their health and wellness.

“We’re proud to be one of the first and only companies to offer consumers a daily tracking solution that provides them a closer look at how their cannabis use affects their personal health and wellness,” stated Doug Chloupek, CEO and Founder of Juva. “One of Juva’s primary goals is to expand our industry’s knowledge of the medicinal effects of cannabis from a scientific perspective. The Journal App provides a personal tracking solution for our customers and it gives Juva information that compliments the data we collect via our research registry.”

Through the Journal App, cannabis consumers and anyone who uses hemp-based CBD products can track their symptoms, medication use and results.

“In all industries, data is king. Through both the Journal App and our WIRB-approved registry, we are curating one of the largest repositories of real-world data on the medical effects of cannabis use, including consumption behavior and perceived effectiveness. While we remain committed to the privacy of our users, the data we are collecting will be beneficial from a regulatory and scientific standpoint and adds significant value to Juva’s intellectual property portfolio,” added Chloupek. “All user info associated with the Journal App and the WIRB-approved registry is protected by the strictest patient privacy laws in the world, so participants can rest assured their entries are 100% confidential; any data imputed is anonymized for patient privacy.”

Study And Research

The company is also running a WIRB-approved multi-year study through its cannabis research registry. Once completed Juva will have one of the largest data sets of its kind and be able to leverage the data in both its nutraceutical wellness, drug development and clinical programs. This real-world observational data, overseen by physicians and clinicians, will be presented to various regulatory bodies to show the potential therapeutic benefits of cannabis and hemp-derived compounds.

Juva Life also has a pharmaceutical research and life sciences division, with a goal of identifying the mode of action behind cannabis’ anecdotal ability to regulate inflammation. The company recently identified non-cannabinoid compounds JUVA-019 and JUVA-041, on which the company has filed patent applications and has conducted preclinical research showing the compound is effective as a stand-alone compound in inhibiting inflammation by modulating certain biomarkers in the body. JUVA-019 and JUVA-041, which the company has nominated as drug candidates for further preclinical investigation, are currently advancing through phenotypic models of chronic diseases of aging.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.